当前位置: X-MOL 学术Lett. Drug Des. Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
L-carnitine Supplementation Improves Self-rating Depression Scale Scores in Uremic Male Patients Undergoing Hemodialysis
Letters in Drug Design & Discovery ( IF 1 ) Pub Date : 2017-06-06 , DOI: 10.2174/1570180814666170216102632
Kyoko Tashiro 1 , Yusuke Kaida 2 , Sho-Ichi Yamagishi 3 , Hideharu Tanaka 2 , Miyuki Yokoro 2 , Junko Yano 2 , Kazuko Sakai 2 , Yuka Kurokawa 2 , Kensei Taguchi 2 , Yosuke Nakayama 2 , Takahiro Inokuchi 1 , Kei Fukami 2
Affiliation  

Background: Depression is highly prevalent in uremic patients undergoing hemodialysis (HD). We previously found that low free-carnitine levels are associated with depression severity in male patients undergoing HD. However, whether L-carnitine supplementation improves the depression state in male patients undergoing HD remains unclear. Methods: Sixteen male patients undergoing HD were orally administered 900 mg L-carnitine daily or intravenously administered 1000 mg L-carnitine immediately after undergoing HD for 3 months. The depression state and various types of carnitine levels were evaluated using the self-rating depression scale (SDS) and tandem mass spectrometry, respectively, at baseline and 3 months after treatment. Results: L-carnitine supplementation significantly increased serum levels of free and other acylcarnitine types, associated with improved SDS scores in male patients undergoing HD. Univariate analysis revealed that low baseline butyryl- and isovaleryl-/2-methylbutyryl-carnitine levels were significantly correlated with SDS scores after treatment. Multiple regression analysis revealed that butyryl-carnitine levels were a sole independent predictor of SDS scores after treatment (r2 = 0.533). Conclusion: L-carnitine supplementation for 3 months improved the depression state in uremic male patients undergoing HD. Thus, low butyryl-carnitine levels may predict the clinical response to L-carnitine supplementation in male patients undergoing HD and who have mild depression.

中文翻译:

左旋肉碱补充剂可提高接受血液透析的尿毒症男性患者的自评抑郁量表评分

背景:在接受血液透析 (HD) 的尿毒症患者中,抑郁症非常普遍。我们以前发现,低游离肉碱水平与接受 HD 的男性患者的抑郁严重程度有关。然而,补充左旋肉碱是否能改善接受 HD 的男性患者的抑郁状态仍不清楚。方法:16 名接受 HD 的男性患者在接受 HD 3 个月后立即口服 900 毫克左旋肉碱或静脉注射 1000 毫克左旋肉碱。分别在基线和治疗后 3 个月使用抑郁自评量表 (SDS) 和串联质谱法评估抑郁状态和各种类型的肉碱水平。结果:左旋肉碱补充剂显着增加了游离和其他酰基肉碱类型的血清水平,与接受 HD 的男性患者的 SDS 评分提高相关。单变量分析显示,低基线丁酰-和异戊酰-/2-甲基丁酰-肉碱水平与治疗后的 SDS 评分显着相关。多元回归分析显示丁酰肉碱水平是治疗后 SDS 评分的唯一独立预测因子(r2 = 0.533)。结论:补充左旋肉碱3个月可改善尿毒症男性HD患者的抑郁状态。因此,低丁酰肉碱水平可以预测接受 HD 和轻度抑郁症的男性患者对左旋肉碱补充剂的临床反应。单变量分析显示,低基线丁酰-和异戊酰-/2-甲基丁酰-肉碱水平与治疗后的 SDS 评分显着相关。多元回归分析显示丁酰肉碱水平是治疗后 SDS 评分的唯一独立预测因子(r2 = 0.533)。结论:补充左旋肉碱3个月可改善尿毒症男性HD患者的抑郁状态。因此,低丁酰肉碱水平可以预测接受 HD 和轻度抑郁症的男性患者对左旋肉碱补充剂的临床反应。单变量分析显示,低基线丁酰-和异戊酰-/2-甲基丁酰-肉碱水平与治疗后的 SDS 评分显着相关。多元回归分析显示丁酰肉碱水平是治疗后 SDS 评分的唯一独立预测因子(r2 = 0.533)。结论:补充左旋肉碱3个月可改善尿毒症男性HD患者的抑郁状态。因此,低丁酰肉碱水平可以预测接受 HD 和轻度抑郁症的男性患者对左旋肉碱补充剂的临床反应。左旋肉碱补充剂 3 个月改善了接受 HD 的尿毒症男性患者的抑郁状态。因此,低丁酰肉碱水平可以预测接受 HD 和轻度抑郁症的男性患者对左旋肉碱补充剂的临床反应。左旋肉碱补充剂 3 个月改善了接受 HD 的尿毒症男性患者的抑郁状态。因此,低丁酰肉碱水平可以预测接受 HD 和轻度抑郁症的男性患者对左旋肉碱补充剂的临床反应。
更新日期:2017-06-06
down
wechat
bug